AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- IonQ, D-Wave, and Rigetti Face Off Ahead of Earnings – Who’s Nearest to Commercial Breakthrough?
- AstraZeneca’s Benralizumab Trial: A Potential Game-Changer for Pediatric Eosinophilic Diseases
- AstraZeneca’s Ravulizumab Study: A New Hope for gMG Patients
- AstraZeneca’s New Study on AZD4954: A Potential Game Changer in Cardiovascular Treatment
- AstraZeneca’s AZD5004 Study: A New Hope for Type 2 Diabetes Treatment?